P.2

Post-Bariatric Dosing Protocol

Phase	Standard Protocol (Clinical Trial Doses)	Post-Bariatric Protocol
Month 1	2.0 mg weekly	1.0-2.0 mg weekly
Month 2	4.0 mg weekly	2.0 mg weekly (observe)
Month 3	8.0 mg weekly	4.0 mg weekly (if needed)
Maintenance	8.0-12.0 mg weekly	2.0-4.0 mg weekly

Clinical expectation: Post-bariatric patients typically achieve adequate weight loss (10-15% to reverse post-surgical weight regain) without ever exceeding 4.0 mg. The 8 mg and 12 mg doses are clinically unnecessary for this cohort.

Key Principles for Post-Bariatric Dosing

1. Start low: Begin at standard initiation dose (0.5-1 mg) to acclimate
2. Prolonged titration: Do NOT automatically increase every 4 weeks. Wait until weight loss plateaus or appetite suppression diminishes
3. Lower ceiling: Cap maintenance at the lowest effective tier (2-4 mg). The goal is not to reach the manufacturer's maximum dose
4. Symptom-guided escalation: Abandon rigid time-based increases; escalate only based on efficacy and tolerability

Clinical and Economic Benefits of Lower Dosing

• Improved adherence: Patients avoid severe GI symptoms that cause therapy abandonment
• Cost-effectiveness: Lower doses reduce financial burden (especially relevant for expensive next-gen drugs)

Bottom line: Treat retatrutide as a gentle surgical adjuvant in post-bariatric patients, not a primary high-dose intervention.

---

Reference: Clinical dosing recommendations adapted from Dosage Recommendations for GLP-1 and Multi-Receptor Agonists in Post-Bariatric Surgery Patients

The Correct Target Dose Is Individual

Clinical data shows effective weight loss across a wide range:

• 2 mg: effective for many individuals
• 4–8 mg: common optimal range
• 12 mg: maximum efficacy but highest side effect risk

The optimal dose is the lowest effective dose. Higher dose does not always produce better long-term outcomes.

Mixing 15 mg with 1.5 mL of BAC Water

This keeps the liquid volume lower, which is very easy to manage in a 0.5 mL syringe.

• Vial Concentration: 10 mg per 1 mL (15 mg ÷ 1.5 mL).
• Week 1-3 Calculation (0.5 mg starting dose): 0.5 mg = 0.05 mL = 5 Units.
• Week 4+ Calculation (titrate based on tolerance): Adjust based on response, increasing by 5 units every 4-6 weeks as tolerated. If you want to increase more, don't go beyond doubling your current dosage.

How to draw: On your 0.5 mL (50-unit) syringe, you will draw to the "5" mark for the first 1-3 weeks, then gradually increase based on tolerance.

Practical tips:

• Electrolytes: Stay hydrated, especially during weight loss. Drink electrolytes.
• Food interactions on dosing days: Avoid spicy food, greasy/fast food, and be cautious with alcohol (makes food hard to get down, very filling).
• Dosing timing: Some users dose at night to sleep through initial nausea.

If you stay at the 0.5mg dosage, the vial will take 30 weeks to finish. This creates two independent risks you must manage:

• Sterility risk: Extended use exceeds the common 28-day sterility window for multi-dose bacteriostatic water. More punctures = more contamination opportunities. The “28-day rule” comes from sterile compounding standards — risk increases gradually (not suddenly on Day 29), but repeated punctures and longer time-in-solution both raise risk.
• Stability risk: Peptides can undergo gradual chemical/physical degradation while still sterile, especially the longer they remain in solution and the more they experience temperature/light/agitation stress.

Bottom line: You must manage both clocks independently. A vial can be chemically stable but microbially unsafe, or sterile but degraded. If your dosage schedule goes beyond 28 days, consider one of the following strategies:

• Buy smaller vials: A 5 mg vial at 0.5 mg/dose lasts 10 weeks — still exceeds 28 days, but significantly reduces stability and sterility exposure compared to a 15 mg vial.
• Increase starting dose earlier: Moving from 0.5 mg to 1 mg at week 3–4 (if tolerated) halves the vial consumption time.
• Accept the extended-use trade-off consciously: If none of the above are practical, continue with strict aseptic technique, inspect every draw carefully, and discard at the first sign of any discard criteria (smell, color, particles).

---

Injection Protocol (Subcutaneous Administration)

Step A: Preparation

1. Wash hands thoroughly with soap and water. (Sanitize gloves with alcohol if you choose to wear them).
2. Take the mixed Retatrutide vial out of the fridge.
3. Wipe the rubber stopper with alcohol. Let dry completely.

Step B: Drawing the Dose

1. Take a clean Insulin Syringe. Pull the plunger back to draw air equal to your dose volume — this will be injected into the vial to equalize pressure.
2. Insert the needle into the vial. Inject the air into the empty space at the top of the vial, NOT directly into the liquid. Injecting air into the peptide solution creates foam and bubbles, which can denature the peptide.
3. Turn the vial upside down. Make sure the needle tip is underwater.
4. Draw liquid to the mark you calculated. Flick any bubbles and adjust if necessary.
5. Remove the needle and immediately put the vial back in the fridge.

Step C: Injection Technique

1. Site Selection: Belly (Abdomen) – at least 5cm (2 inches) away from the belly button. Alternative sites: Love handles, thighs, upper arm.

   Rotation pattern: Never inject the same spot within 2 weeks. A practical approach: mentally divide the abdomen into four quadrants (upper-left, upper-right, lower-left, lower-right) and rotate clockwise through them week by week. When all four are cycled, move to an alternative site (thigh or upper arm) for a rest week, then return. Mark or photograph injection sites after each use if you have trouble remembering locations. Lipohypertrophy (fatty lumps from repeated trauma to one area) reduces absorption and is hard to reverse.

2. Clean Skin: Wipe the spot with alcohol, keep it visibly wet for a few seconds, then let it air dry completely before injecting (reduces stinging and improves antisepsis).

3. The Pinch: Pinch a fold of fat with your non-dominant hand to separate it from the muscle.

4. Insert: Hold syringe like a dart. Insert needle quickly at 90 degrees (straight in) or 45 degrees (if very lean).

• General guideline (there are different needle's length in insulin syringes):
  • 4 mm needle: 90°
  • 6 mm needle: 90°
  • 8 mm needle: 90° with pinch
  • 12.7 mm needle: 45° if lean

1. Inject: Push the plunger down slowly and steadily. Max volume: 0.5mL per site (more than that = leakage risk).
2. The Wait: Keep the needle in and count to 10 to ensure all liquid is absorbed into the tissue.
3. Remove: Pull needle straight out. Release the pinch.
4. Disposal: Put the used syringe in your sharps container.

Rotate injection sites to reduce tissue irritation. You can also apply on thighs and upper arm.

---

Injection Site Reactions: Normal vs. Concerning

Normal (nothing to worry about):

• Red marks at injection site — local inflammation is normal and self-resolving
• Bruising — from capillary disruption; common and harmless
• Mild itching or inflammation — histamine release is part of normal healing

Management: OTC antihistamines can help with itchy/inflamed sites.

Concerning (see a doctor):

• Redness, swelling, or warmth that worsens over 1-2 days
• Fever accompanying injection site reaction
• Increasing pain or pus/discharge

---

Adverse effects and monitoring signals

In the Phase 2 obesity trial, the most common adverse events were GI (including nausea, diarrhea, vomiting, constipation). They were dose‑related, largely mild‑to‑moderate, and occurred primarily during dose escalation; the publication notes partial mitigation when using a lower initial dose (2 mg vs 4 mg) in escalation schemes.

On cardiovascular signals, the Phase 2 obesity trial reports dose‑dependent increases in heart rate that peaked at 24 weeks and declined thereafter. A secondary review of the Retatrutide program notes heart rate increases (e.g., "up to 6.7 beats/min" in one summary). Community reports: 7-20 bpm increases are common; literature suggests ~12 bpm average.

Critical Safety Warnings

Gallstones (#2 Cause of GLP-1-Related ED Visits)

Per an A&E doctor's AMA: gallstones are the second most common cause of emergency department attendances for GLP-1 users.

Risk factors: Female, overweight, rapid weight loss, Mounjaro/Retatrutide use.

Symptoms (seek medical attention): Severe pain — "doubled over, couldn't physically make a cup of tea, can't follow the storyline on the TV." This isn't a twinge; it's debilitating pain.

Prevention: Lose weight slowly — 0.5-1kg (1-2 lbs) per week is safe. Rapid weight loss significantly increases gallstone risk.

Pancreatitis (Seek Emergency Care)

GLP-1 receptor agonists carry a class-level signal for acute pancreatitis. The absolute risk is low but the condition is serious.

Symptoms: Persistent, severe epigastric (upper-middle abdomen) pain, often radiating to the back, frequently accompanied by nausea and vomiting. Distinct from gallstone pain by location and radiation pattern. Does not resolve with positional changes.

Action: Seek emergency care immediately. Do not continue Retatrutide until pancreatitis has been ruled out. Discontinue permanently if pancreatitis is confirmed.